Silver Book Fact

Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.

Watson J, Allen S, Dawbarn D. Targeting New Growth Factor in Pain: What is the therapeutic potential?. BioDrugs. 2008; 22(6): 349-59. http://www.mendeley.com/catalog/targeting-nerve-growth-factor-pain-therapeutic-potential/

Reference

Title
Targeting New Growth Factor in Pain: What is the therapeutic potential?
Publication
BioDrugs
Publication Date
2008
Authors
Watson J, Allen S, Dawbarn D
Volume & Issue
Volume 22, Issue 6
Pages
349-59
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A meta-analysis of duloxetine, an anti-depressant, found a 50% reduction in pain at 12 weeks for diabetic peripheral neuropathy, and a 50% reduction in pain at 12 weeks for fibromyalgia.  
  • An oral cannabinoid was found effective in relieving diabetic peripheral neuropathic pain symptoms and improving disturbed sleep, quality of life, and overall patient status.  
  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.  
  • Topical capsaicin was found in a meta-analysis to provide a degree of pain relief to some patients with painful neuropathic conditions.  
  • The combination of information for neuroimaging and circulatory biomarkers could improve both the sensitivity and specificity of pain diagnosis and thereby improve treatment.